ViroLogic Announces the Promotion of Michael Bates, M.D., to Vice President of Clinical Research

ViroLogic Announces the Promotion of Michael Bates, M.D., to Vice
President of Clinical Research 


SOUTH SAN FRANCISCO, Calif., June 22  /PRNewswire-FirstCall/ -- ViroLogic, Inc.
(NASDAQ:VLGC) announced today that Michael Bates, M.D., has been promoted to
the position of Vice President, Clinical Research. Dr. Bates will manage the
Company's clinical programs and will report directly to Chairman and CEO Bill
Young.

"Mike serves as a driving force of our clinical research program and a key
contributor to our physician education initiatives, chairing Drug Resistance
Forums and presenting to the HIV physician community. He has made many
important contributions to ViroLogic as a collaborator with academic
institutions and life sciences companies," said Bill Young. "Mike is a true
visionary who firmly believes in personalized medicine. In his new role, Mike
will be able to build on his accomplishments in HIV and apply his understanding
of disease management and immunology as ViroLogic expands into other diseases."

Dr. Bates joined the Clinical Research group at ViroLogic, Inc., as Medical
Director in January 2001 and was promoted to Senior Director in 2003.
Previously, Dr. Bates served as Regional Medical Director/Medical Liaison for
Roche, focusing on virology. Dr. Bates completed his internship and residency
in Internal Medicine at the University of California, San Francisco, before
pursuing fellowship training in Cardiology at Duke University in Durham, North
Carolina, and in Infectious Diseases at the University of Washington in
Seattle, Washington.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious viral diseases such as AIDS and hepatitis. The Company's
products are designed to help doctors optimize treatment regimens that lead to
better patient outcomes and reduced costs. ViroLogic's technology is also being
used by numerous biopharmaceutical companies to develop new and improved
anti-viral therapeutics and vaccines targeted at emerging drug-resistant
viruses. More information about the Company and its technology can be found on
its web site at http://www.virologic.com/.

Certain statements in this press release are forward-looking. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements.  These risks and uncertainties include, but are not limited to,
whether ViroLogic successfully introduces new products, whether others
introduce competitive products, the risk that the Company's products for
patient testing may not continue to be accepted or that increased demand from
drug development partners may not develop as anticipated, the risk that gross
margins may not increase as expected, the risk that ViroLogic may not continue
to realize anticipated benefits from its cost-cutting measures, the timing of
pharmaceutical company clinical trials, whether payors will authorize
reimbursement for its products, whether the FDA or any other agency will decide
to regulate ViroLogic's products or services, whether the Company will
encounter problems or delays in automating its processes, whether intellectual
property underlying the Company's PhenoSense technology is adequate, whether
licenses to third party technology will be available, whether ViroLogic is able
to build brand loyalty and expand revenues, and whether ViroLogic will be able
to raise sufficient capital when required.  For a discussion of other factors
that may cause ViroLogic's actual events to differ from those projected, please
refer to the Company's most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as other subsequent filings with the Securities
and Exchange Commission. 

DATASOURCE: ViroLogic, Inc.



CONTACT:  Karen Wilson, CFO of ViroLogic, [phone], or





Web site:  http://www.virologic.com/

Copyright